Clinical Trial Update: A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Paricalcitol For Treatment of Secondary Hyperparathyroidism (SHPT) in Pediatric Participants With Stage 5 Chronic Kidney Disease (CKD) [Phase 3]

View source ↗

Summary

Phase 3 clinical trial assessing safety, efficacy and pharmacokinetics of paricalcitol for secondary hyperparathyroidism in pediatric patients with stage 5 chro…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• Hyperparathyroidism

Drugs mentioned

• Paricalcitol (paricalcitol)

Snippet

Sponsor: AbbVie | Conditions: Chronic Kidney Disease (CKD), Secondary Hyperparathyroidism (SHPT) | Phase 3 | Status: TERMINATED